CID-103

Monoclonal antibody

Earlyevidence

Evidence outlook

Mid-stage study registered, not yet recruiting

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Also in development:Multiple Myeloma · Phase 1

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Immune Thrombocytopenia
NCT07946549 · CASI pharmaceuticals, Inc.
2026-11-30 – 2029-01-31 · Chronic Immune Thrombocytopenia
What this study did
Phase 1/2 (2)
Immune Thrombocytopenia
Other / comorbidity
NCT07641426 · CASI pharmaceuticals, Inc.
2026-06-09 – 2030-12 · Antibody Mediated Rejection
What this study did
Phase 1 (1)
Multiple Myeloma

Competitive landscape

This mechanism is crowded: 13 other tracked programmes target it, 11 of them ahead of this one.

This drug's own stage for Immune Thrombocytopenia: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
CID-103: this drugPhase 2Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
Fostamatinib (Tavalisse)ApprovedSmall moleculeSpleen tyrosine kinase (Syk)not yet gradedNo reviewed efficacy summary in this indication
RilzabrutinibApprovedSmall moleculeBTKReliable signalNo reviewed efficacy summary in this indication
Mezagitamab
Phase 3(overall)
Monoclonal antibodyCD38
Weak signal(overall)
No reviewed efficacy summary in this indication

Compare side by side

5 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow CID-103 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
November 2028 (1)
Phase 2Immune ThrombocytopeniaNot yet recruiting
Est. primary completion 2028-11-30 · NCT07946549 · CT.gov ↗
What to watch
2030 (1)
May 2030 (1)
Phase 1/2Antibody Mediated RejectionRecruiting
Est. primary completion 2030-05 · NCT07641426 · CT.gov ↗
What to watch

See the full readout calendar ↗